AU754352B2 - Medicament - Google Patents
Medicament Download PDFInfo
- Publication number
- AU754352B2 AU754352B2 AU38397/97A AU3839797A AU754352B2 AU 754352 B2 AU754352 B2 AU 754352B2 AU 38397/97 A AU38397/97 A AU 38397/97A AU 3839797 A AU3839797 A AU 3839797A AU 754352 B2 AU754352 B2 AU 754352B2
- Authority
- AU
- Australia
- Prior art keywords
- protein
- reg
- seq
- tissue
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims description 18
- 108090000623 proteins and genes Proteins 0.000 claims description 61
- 102000004169 proteins and genes Human genes 0.000 claims description 58
- 210000004116 schwann cell Anatomy 0.000 claims description 44
- 210000002569 neuron Anatomy 0.000 claims description 33
- 239000003226 mitogen Substances 0.000 claims description 31
- 238000000034 method Methods 0.000 claims description 30
- 230000008929 regeneration Effects 0.000 claims description 29
- 238000011069 regeneration method Methods 0.000 claims description 29
- 230000001172 regenerating effect Effects 0.000 claims description 19
- 238000011161 development Methods 0.000 claims description 12
- 230000018109 developmental process Effects 0.000 claims description 12
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 12
- 230000008569 process Effects 0.000 claims description 11
- 239000003085 diluting agent Substances 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 239000003937 drug carrier Substances 0.000 claims description 7
- 230000008439 repair process Effects 0.000 claims description 7
- 240000007594 Oryza sativa Species 0.000 claims 1
- 235000007164 Oryza sativa Nutrition 0.000 claims 1
- 235000009566 rice Nutrition 0.000 claims 1
- 101100412394 Drosophila melanogaster Reg-2 gene Proteins 0.000 description 90
- 210000002161 motor neuron Anatomy 0.000 description 36
- 210000001519 tissue Anatomy 0.000 description 30
- 210000003050 axon Anatomy 0.000 description 24
- 230000014509 gene expression Effects 0.000 description 24
- 238000002869 basic local alignment search tool Methods 0.000 description 19
- 210000001044 sensory neuron Anatomy 0.000 description 18
- 210000003497 sciatic nerve Anatomy 0.000 description 13
- 230000000694 effects Effects 0.000 description 11
- 210000000578 peripheral nerve Anatomy 0.000 description 10
- 108020003175 receptors Proteins 0.000 description 10
- 102000005962 receptors Human genes 0.000 description 10
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- 239000002773 nucleotide Substances 0.000 description 9
- 125000003729 nucleotide group Chemical group 0.000 description 9
- 102000004127 Cytokines Human genes 0.000 description 8
- 108090000695 Cytokines Proteins 0.000 description 8
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 8
- 102100032352 Leukemia inhibitory factor Human genes 0.000 description 8
- 241000700159 Rattus Species 0.000 description 8
- 230000006378 damage Effects 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 102100021747 Leukemia inhibitory factor receptor Human genes 0.000 description 7
- 208000027418 Wounds and injury Diseases 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 208000014674 injury Diseases 0.000 description 7
- 108020004999 messenger RNA Proteins 0.000 description 7
- 230000011664 signaling Effects 0.000 description 7
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 230000002093 peripheral effect Effects 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 102000038778 CNTF family Human genes 0.000 description 5
- 108091064557 CNTF family Proteins 0.000 description 5
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 5
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 5
- 101001042362 Homo sapiens Leukemia inhibitory factor receptor Proteins 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 230000004663 cell proliferation Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 210000005036 nerve Anatomy 0.000 description 5
- 210000000278 spinal cord Anatomy 0.000 description 5
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 4
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 4
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 4
- 108050003475 Neuregulin Proteins 0.000 description 4
- 102000014413 Neuregulin Human genes 0.000 description 4
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 4
- 210000002257 embryonic structure Anatomy 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- DVGHHMFBFOTGLM-UHFFFAOYSA-L fluorogold Chemical compound F[Au][Au]F DVGHHMFBFOTGLM-UHFFFAOYSA-L 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 230000002297 mitogenic effect Effects 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 230000001537 neural effect Effects 0.000 description 4
- 210000001428 peripheral nervous system Anatomy 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- 230000014616 translation Effects 0.000 description 4
- 102100028892 Cardiotrophin-1 Human genes 0.000 description 3
- 102000008080 Pancreatitis-Associated Proteins Human genes 0.000 description 3
- 108010074467 Pancreatitis-Associated Proteins Proteins 0.000 description 3
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 3
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 108010041776 cardiotrophin 1 Proteins 0.000 description 3
- 230000002518 glial effect Effects 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 238000011065 in-situ storage Methods 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 210000003594 spinal ganglia Anatomy 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 101710142062 Leukemia inhibitory factor receptor Proteins 0.000 description 2
- 101150071228 Lifr gene Proteins 0.000 description 2
- 102000003797 Neuropeptides Human genes 0.000 description 2
- 108090000189 Neuropeptides Proteins 0.000 description 2
- 108090000099 Neurotrophin-4 Proteins 0.000 description 2
- 102100033857 Neurotrophin-4 Human genes 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 206010033645 Pancreatitis Diseases 0.000 description 2
- 101100120298 Rattus norvegicus Flot1 gene Proteins 0.000 description 2
- 101100412403 Rattus norvegicus Reg3b gene Proteins 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- -1 carrier Substances 0.000 description 2
- 230000007348 cell dedifferentiation Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000000428 dust Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 229940100601 interleukin-6 Drugs 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 238000010845 search algorithm Methods 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 1
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 102100034613 Annexin A2 Human genes 0.000 description 1
- 108090000668 Annexin A2 Proteins 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 1
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 1
- 102000004414 Calcitonin Gene-Related Peptide Human genes 0.000 description 1
- 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 239000012983 Dulbecco’s minimal essential medium Substances 0.000 description 1
- 239000004150 EU approved colour Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000617830 Homo sapiens Sterol O-acyltransferase 1 Proteins 0.000 description 1
- 101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 description 1
- 241000251109 Hydrochara major Species 0.000 description 1
- 102000010781 Interleukin-6 Receptors Human genes 0.000 description 1
- 108010038501 Interleukin-6 Receptors Proteins 0.000 description 1
- 230000004163 JAK-STAT signaling pathway Effects 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 101710143474 Lectin-related protein Proteins 0.000 description 1
- 102000004058 Leukemia inhibitory factor Human genes 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 239000012580 N-2 Supplement Substances 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 206010056677 Nerve degeneration Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101150073131 PAP gene Proteins 0.000 description 1
- 108091008606 PDGF receptors Proteins 0.000 description 1
- 206010033647 Pancreatitis acute Diseases 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102100027336 Regenerating islet-derived protein 3-alpha Human genes 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 206010039670 Sciatic nerve injury Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 102100021993 Sterol O-acyltransferase 1 Human genes 0.000 description 1
- 101000697584 Streptomyces lavendulae Streptothricin acetyltransferase Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 102100023132 Transcription factor Jun Human genes 0.000 description 1
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 201000003229 acute pancreatitis Diseases 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000004227 basal ganglia Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 230000008614 cellular interaction Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 230000009510 cerebral cortex damage Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229940095074 cyclic amp Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 238000010410 dusting Methods 0.000 description 1
- 231100000318 excitotoxic Toxicity 0.000 description 1
- 230000003492 excitotoxic effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 210000000609 ganglia Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000005230 lumbar spinal cord Anatomy 0.000 description 1
- 210000004705 lumbosacral region Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000001095 motoneuron effect Effects 0.000 description 1
- 230000003988 neural development Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 230000000508 neurotrophic effect Effects 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 229940097998 neurotrophin 4 Drugs 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000009984 peri-natal effect Effects 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000026447 protein localization Effects 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000007441 retrograde transport Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/474—Pancreatic thread protein; Reg protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Description
A.
AUSTRALIA
Patents Act 1990 "MEDIAL RESEARCH COUNCIL
ORIGINAL
COMPLETE SPECIFICATION STANDARD PATENT Invention Title: Medicament
S
S
S
S.
S 55 S S
*S
S
S S
S.
The following statement is a full description of this invention including the best method of performing it known to us:- The present invention relates to a medicament. In particular, the present invention relates to a medicament that can be used to affect the development repair and/or regeneration) of neuronal cells or tissue.
Motor neurons are the only adult mammalian central neurons that have the capability to regenerate following injury'. This ability is dependent on the environment of the peripheral nerve and an intrinsic capacity of motor neurons for regrowth 2 For example, Schwann cell dedifferentiation and proliferation are considered to be essential for neural regeneration in the adult peripheral nervous system 5 6. The currently known Schwann cell mitogens, such as the glial growth factors/neuregulins, are consitutively expressed by motor and sensory neurons in early development and 15 adulthood 24 but are not upregulated during regeneration However, regeneration of neuronal tissue is by no means guaranteed following injury and so it is desirable to have compounds and compositions that could be used for the beneficial treatment of damaged neuronal cells or tissue.
The present invention seeks to provide compounds and compositions useful for the beneficial treatment of damaged neuronal cells or tissues.
According to a first aspect of the present invention there is provided the use of a protein comprising the sequence presented as SEQ ID No. 1 or a variant, derivative or homologue thereof in the manufacture of a medicament to act as a Schwann cell mitogen.
According to a second aspect of the present invention there is provided a medicament comprising a protein comprising the sequence presented as SEQ ED No. 1 or a variant, derivative or homologue thereof optionally admixed with a pharmaceutically acceptable carrier, diluent or excipient.
According to a third aspect of the present invention there is provided a medicament comprising a protein comprising the sequence presented as SEQ ID No. 1 or a variant, derivative or homologue thereof optionally admixed with a pharmaceutically acceptable carrier, diluent or excipient, and wherein the protein is in an effective amount to act as a Schwann cell mitogen.
According to a fourth aspect of the present invention there is provided a method of 000f: treatment comprising administering to a subject a protein comprising the sequence presented as SEQ ID No. 1 or a variant, derivative or homologue thereof and wherein 15 the protein affects the development repair and/or regeneration) a neuronal cell or tissue.
According to a fifth aspect of the present invention there is provided a method of treatment comprising administering to a subject a protein comprising the sequence 20 presented as SEQ ID No. 1 or a variant, derivative or homologue thereof and wherein the protein acts as a Schwann cell mitogen.
a According to a sixth aspect of the present invention there is provided a method of treatment comprising administering to a subject a protein comprising the sequence presented as SEQ ID No. 1 or a variant, derivative or homologue thereof and wherein the protein is in an amount to cause regeneration of at least some neuronal cells or tissue.
According to a seventh aspect of the present invention there is provided a process of repairing and/or regenerating a neuronal cell or tissue, the process comprising contacting a damaged neuronal cell or tissue with a protein comprising the sequence presented as SEQ ID No. 1 or a variant, derivative or homologue thereof, and allowing repair and/or regeneration of at least some of the neuronal cell or tissue.
Other aspects of the present invention include medicaments comprising the protein of the present invention that are suitable for use in the above-mentioned processes and methods.
In a broader sense, the present invention also provides a Schwann cell mitogen that is capable of being upregulated during regeneration of neuronal cells or tissue.
The protein shown as SEQ ID No. 1 is sometimes called Reg-2.
oo 15 One of the advantages of the present invention is that we have now shown that Reg-2 can act as a Schwann cell mitogen which in turn means that a damaged neuronal cell or tissue iV can be repaired (at least partially repaired) and/or regenerated.
A further advantage of the present invention is that we have also found that Reg-2 is up- S 20 regulated. This is advantageous in that administration of Reg-2 to induce neuronal cell or tissue repair may result in expression of endogenous Reg-2, possibly leading to even S. further neuronal cell or tissue repair.
In a highly preferred embodiment the protein of the present invention is not the naturally occuring protein i.e. it is not the naturally occurring protein in its natural environment and when expressed by endogenous coding sequences in their natural environment under the control of their naturally associated regulatory elements which are also in their natural environment.
Thus, in a highly preferred embodiment the protein of the present invention is an exogenous protein.
In a preferred embodiment, the protein has the sequence presented as SEQ ID No. 1.
Hence, preferred emdodiments of the present invention are: i. Use of a protein having the sequence presented as SEQ ID No. 1 thereof in the manufacture of a medicament to act as a Schwann cell mitogen.
ii. A medicament comprising a protein having the sequence presented as SEQ ID No. 1 optionally admixed with a pharmaceutically acceptable carrier, diluent or excipient.
iii. A medicament comprising a protein having the sequence presented as SEQ ID 0 S: No. 1 optionally admixed with a pharmaceutically acceptable carrier, diluent or S: 15 excipient, and wherein the protein is in an effective amount to act as a Schwann cell mitogen.
iv. A method of treatment comprising administering to a subject a protein having the sequence presented as SEQ ID No. 1 and wherein the protein affects the development 20 repair and/or regeneration) of neuronal cell or tissue.
v. A method of treatment comprising administering to a subject a protein having the sequence presented as SEQ ID No. 1 and wherein the protein acts as a Schwann cell mitogen.
vi. A method of treatment comprising administering to a subject a protein having the sequence presented as SEQ ID No. 1 and wherein the protein is in an amount to cause regeneration of at least some neuronal cells or tissue.
vii. A process of repairing and/or regenerating a neuronal cell or tissue, the process comprising contacting a damaged neuronal cell or tissue with a protein having the sequence presented as SEQ ID No. 1 and allowing repair and/or regeneration of at least some of the neuronal cell or tissue.
The protein may be isolated from natural sources or it may be prepared synthetically. In a preferred embodiment, it is prepared by use of recombinant DNA techniques such as by expression of the nucleotide sequence presented as SEQ ID No. 2 by a suitable expression system.
In the process of the present invention, some or all of the neuronal cells or tissue may be repaired and/or regenerated (or combinations thereof) in vitro ex vivo namely not in a whole living organism) and then optionally introduced into a subject.
g 15 Alternatively, in the process of the present invention, the neuronal cell or tissue may be repaired and/or regenerated (or combinations thereof) in vivo in a subject.
Preferably, the neuronal cell or tissue is from or is in an adult animal.
20 More preferably, the neuronal cell or tissue is from or in an adult human.
S
S•Preferably the neuronal cell or tissue is a motor neuronal cell or tissue.
The term "subject" includes any one or more different types of animal, including humans. Preferably, the term means a human.
The term "variant, derivative or homologue" in relation to the protein of the present invention includes any substitution of, variation of, modification of, replacement of, deletion of or addition of one (or more) amino acid from or to the sequence providing the resultant amino acid sequence has the capability to act as a Schwann cell mitogen, preferably having at least the same activity as the enzyme shown as SEQ I.D. No. 1. In particular, the term "homologue" covers homology with respect to structure and/or sequence and/or function. With respect to sequence homology similarity), preferably there is at least 75%, more preferably at least 85%, more preferably at least homology to the sequence shown as SEQ ID No.1 in the attached sequence listings. More preferably there is at least 95%, such as at least 98%, homology to the sequence shown as SEQ ID No. 1 in the attached sequence listings.
The term thus also includes active fragments of the protein but wherein those fragments are also capable of acting as a Schwann cell mitogen.
The term "Schwann cell mitogen" means that the protein of the present invention may independently act as a mitogen of Schwann cells or it may act together with one or more other co-factors (such as a receptor) as a mitogen of Schwann cells.
20 Thus in accordance with a preferred aspect of the present invention we have found that it is possible to regenerate motor neurons by use of a novel Schwann cell mitogen. In this regard, we have found that the protein of the present invention may act as a Schwann cell mitogen.
The present invention will now be described only by way of example, in which reference is made to the following Figures: Figure 1 which shows photograph images; Figure 2 which shows photograph images; Figure 3 which shows a diagram and two graphs; Figure 4 which shows two graphs; and Figure 5 which shows photograph images.
EXPERIMENTAL
METHODS
In vivo regeneration studies All surgery was carried out according to U.K. Home Office guidelines for the ethical treatment of animals. Sciatic nerve crush, tissue fixation and tissue recovery were carried 15 out as described in the art 26 Leukaemia inhibitory factor receptor mutant and wild-type mouse embryos were bred and genotyped as described in the art 7 Regenerating motor neurons were retrogradely labelled by injection of Fluorogold (5 l1 of a 7% solution in PBS) into the proximal stump of the sciatic nerve following axotomy.
Intraneural injection of either pre-immune or anti-Reg-2 antisera was carried out immediately before sciatic nerve crush by injection of 5pl of polyclonal antiserum, raised in rabbit against the whole recombinant protein, into the crush site. Four days later, animals (n=4 for each treatment) were sacrificed and fixed as described above. Tissue from each experiment was coded prior to sectioning and all counts were performed blind.
mRNA differential display Differential display PCR on total cellular RNA extracted from control and regenerating dorsal root ganglia was carried out as described in the art 3 The sequences of cloned cDNAs were compared to the GenBank non-redundant and EST databases using the BLAST algorithm 27 8 In situ hybridisation Oligonucleotides 45 bases in length complementary to the sequence of rat Reg-2 isolated in this screen were synthesised in-house at the LMB core facility. The sequence was: TGG GAG CCT TTG GGG CAA CTA ATG CGT GCA GAG GGT ATT TTC TTC.
The oligonucleotide was 3'-tailed with 35S-a-dATP and hybridised to 15pm sections of 28 developing, lesioned and adult tissues as described 28 Immunohistochemistry Polyclonal antisera or monoclonal antibodies to Reg-2, CGRP (Affmiti), S100 (Dako) and BrdU (Boehringer) were applied to tissue sections or fixed cells at 4°C for 48 hours.
Antibody detection and visualisation were carried out as described in the art 2 Controls for each antibody consisted of a preabsorption with recombinant Reg-2 for the Reg-2 polyclonal antiserum and omission of the first antibody or antiserum from the process for all others. For the in vivo Reg-2 inhibition experiments, a control experiment to detect any residual anti-Reg-2 antiserum within the tissue from the original procedure was S 20 carried out by omitting the Reg-2 polyclonal antiserum and directly applying the appropriate secondary antibody and carrying out the standard detection procedures.
Schwann cell culture Primary cultures of dissociated Schwann cells were prepared from the sciatic nerve of neonatal rats and maintained in Dulbecco's minimal essential medium plus N2 supplement as described in the art 29 Basic FGF (50 ng/ml; Sigma), recombinant Reg-2 (at a range of concentrations from 2-100 ng/ml; produced as described in the art 3 and forskolin Sigma) were added to cultures 24 hours after plating, along with 10pm romodeogyuridine (BrdU)= 24 hours later, cultures were fixed and the cells were processed for BrdU and S100 immunohistochemistry. The proportion of S100-positive cells which were also BrdU-positive was calculated in three separate experiments. The capacity of the anti-Reg-2 antiserum to inhibit Reg-2 signalling in vitro was assessed by measuring the ability of a range of concentrations of antiserum to attenuate the mitogenic effect on Schwann cells of a fixed dose of Reg-2 (30 ng/ml).
RESULTS
The results are presented in the attached Figures, details on which are as follows.
Figure 1. Figure la, mRNA differential display gel comparing gene expression in resting dorsal root ganglia (DRGs; Control, lanes 1 and 2) with that in regenerating DRGs (Regen, lanes 3 and Arrow indicates a 600 bp cDNA expressed solely in regenerating DRGs which encodes Reg-2. b, confirmation by in situ hybridisation of the induction of S.Reg-2 expression in regenerating sensory neurons. Arrows indicate Reg-2 expressing neurons. c, Reg-2 expression in spinal cord motor neurons projecting into the regenerating sciatic nerve (arrows) in a coronal section of the lumbar spinal cord. Scale bars: b, 100pm; c, 200[im.
Figure 2. Reg-2 protein localisation in regenerating motor neurons, a, longitudinal 20 section through the pool of regenerating sciatic nerve motor neurons, retogradely labelled with Fluorogold. b, fluorescent micrograph of Reg-2 immunoreactivity in the same S* section. Almost all regenerating motor neurons express Reg-2. c, Reg-2 is orthogradely transported along regenerating axons in the peripheral nerve, as demonstrated by Reg-2 immunoreactivity in the peripheral axons proximal, but not distal, to the site of peripheral nerve ligation. Scale bars in all figures 250[pm.
Figure 3. Figure 3a, Experimental procedure. Antisera were injected into the hatched area, the dotted line indicating the site of nerve crush. Arrows indicate the two points at which the number of axons containing either CGRP or Reg-2 crossing, each 'point in a longitudinal section were counted. A measure of the number of axons, ciossing the 3mm and 6mm points was obtained by counting all of the labelled axpoial'profiles in focus in a single, optimal focal plane in four sections from each nerve. b, reduction in the number of Reg-2 containing axons crossing two points distal to the site of injury following inhibition of Reg-2 activity in vivo. p<0.001 at each distance (Student's t-test). c, effects of inhibiting Reg-2 activity on the regeneration of CGRP-containing axons; p 890.2 at each distance.
Figure 4. Reg-2 is a Schwann cell mitogen in vitro, a, graph illustrating the percentage of Schwann cells double-labelled for BrdU incorporation (an indicator of DNA synthesis) and S100 (a Schwann cell marker) in the 24 hours following each treatment. Bars indicate the mean percentage of Schwann cells double-labelled for BrdU averaged over three separate experiments, error bars indicate FK forskolin; FGF basic fibroblast growth factor; Reg recombinant Reg-2 protein. b, dose-response curve for the mitogenic effect of Reg-2 on Schwann cells in the presence of 10 =B5m forskolin. Error bars indicate s.e.m.'s.
Figure 5. Reg-2 is a Schwann cell mitogen in vitro. Figure 5a, Reg-2 protein expression in the neonatal spinal cord 24 hours after unilateral sciatic nerve axotomy. Reg-2 is constitutively .expressed in the pool of motor neurons projecting into the sciatic nerve (arrowhead). On the side of axotomy, Reg-2 expression has decreased to low levels, b-e, 20 confocal scanning laser photomicrographs of Reg-2 protein expression in the lumbar spinal cords of wild-type (WT) and leukaemia inhibitory factor mutant mouse embryo littermates. b, c Reg-2 in motor neurons and DRG of E15 WT spinal cord. d, e, absence of Reg-2 expression in the spinal cord and DRG of E15 LIFR mouse embryos. Expression was studied in three WT, three LIFR mutant heterozygotes and three LIFR mutant homozygotes. Scale bars, a, 100~m; b d, 150 pm; c e, 120p.m.
11
DISCUSSION
We report here on the identification by mRNA differential display 3 of an extracellular signalling molecule, previously described as the pancreatic secreted protein Reg-2 4 which is expressed solely in regenerating and developing rat motor and sensory neurons.
Axon-stimulated Schwann cell proliferation is necessary for successful regeneration 5 6, and Reg-2 is a potent Schwann cell mitogen in vitro. In vivo, Reg-2 protein is transported along regrowing axons and inhibition of Reg-2 signalling significantly retards the regeneration of Reg-2-containing axons. During development, Reg-2 production by motor and sensory neurons is regulated by contact with peripheral targets. Strong candidates for peripheral factors regulating Reg-2 production are cytokines of the LIF/CNTF family, as Reg-2 is not expressed in developing motor or sensory neurons of mice carrying a targeted disruption of the LIF receptor gene, a common component of the receptor complexes for all of the LIF/CNTF family 7 Here, CNTF stands for ciliary neurotrophic factor.
Reg-2 is a 16 kD secreted protein which belongs to a family of similar proteins found in the pancreas and gastrointestinal tract under normal and pathological conditions 4 8, 9. A closely related protein, Reg-1, is an islet cell mitogen and is expressed in developing and Alzheimer's disease-affected human cerebral cortex' t 1. Reg-2 is not normally expressed 20 in the adult rat central or peripheral nervous system. Within twenty-four hours of sciatic nerve crush, all motor neurons and a subpopulation of sensory neurons express high levels of Reg-2 mRNA and protein (Figs. lb c; 2a b) and continue to do so for the period of regeneration. The expression of Reg-2 is specific to regenerating motor and sensory neurons, as it is not expressed following a variety of other neuronal lesions, including mechanical and ischaemic cerebral cortex injuries and excitotoxic lesions of the basal ganglia. Nerve crush and injection of the retrograde tracer Fluorogold into the proximal nerve indicated that Reg-2 is expressed by virtually all regenerating sciatic nerve motor neurons Fig. 2a but only by a population of medium to large-sized sensory neurons average cell diameter, 39.7±0.8 pm). Retrograde tracing of muscle afferents by injection of Fluorogold into muscle and double-labelling 'with Reg-2 or double-labelling of sensory neurons for the neuropeptide calcitoni .gene-related peptide 12 (CGRP) and Reg-2 three to seven days after sciatic nerve crush indicated that Reg-2 containing sensory neurons do not project to muscle and only a very small number co-express CGRP (data not shown). Reg-2 protein is orthogradely transported along growing motor and sensory axons, as demonstrated by the accumulation of Reg-2 protein proximal to the site of a peripheral nerve ligation (Fig. 2c). In situ hybridisation with a Reg-2 mRNA specific oligonucleotide probe demonstrated that Reg-2 is not transcribed in the resting or regenerating peripheral nerve. During rat development, Reg-2 is not expressed before embryonic day 15 (Fig. 5b, At this stage, Reg-2 protein is expressed by motor and sensory neurons, and no other cell type, and is expressed in some motor and sensory neurons until the fifth postnatal day.
In order to investigate the possible role of this protein in regeneration in vivo, the effect of inhibiting Reg-2 signalling in the sciatic nerve during regeneration was investigated.
Reg-2 signalling was inhibited in vivo by intraneural injection of an anti-Reg-2 polyclonal 15 antiserum which blocks the mitogenic effects of Reg-2 in vitro. Four days after nerve crush and antiserum administration, the number of Reg-2-containing axons crossing a point 3 mm from the site of injury was reduced to approximately one-third compared to Reg-2-containing axons in animals treated with pre-immune serum (18.3±1.6 Reg-2 containing axons/section at 3mm distal from the injury site in control animals, compared 20 to 6.3±1 Reg-2 containing axons/section at 3mm distal from the injury site in animals treated with anti-Reg-2 antiserum; see Fig. 3 for details). This effect was specific for Reg-2 containing axons. The regeneration of axons containing the neuropeptide CGRP was slightly reduced in the same series of experiments (from an average of 116±8 axons/section to 103±13 axons/section following Reg-2 inhibition; Fig. although this did not reach significance However, CGRP-containing axons are a mixture of motor and sensory axons 12 the motor axons of which also express Reg-2, while the majority of CGRP-expressing sensory neurons do not co-express Reg-2 of CGRP-containing sensory neurons co-express Reg-2).
Given the effects of blocking Reg-2 signalling in vivo and the temporal expression of Reg-2 during development, the effect of Reg-2 on Schwann cell proliferation in vitro was examined. There is a possibility that recombinant Reg-2 on its own acts as a weak mitogen for Schwann cells in vitro (Fig. as do other known Schwann cell mitogens, such as basic fibroblast growth factor (bFGF) and platelet-derived growth factor (PDGF) 3 However, in the presence of forskolin, an activator of adenylate cyclase, Reg-2 is strongly mitogenic for Schwann cells (Fig. This is a well-described phenomenon for other known Schwann cell mitogens, including the glial growth factors (GGFs), bFGF and PDGF, and is attributed to a cAMP-induced increase in receptor expression for those factors 6, 14. To test the hypothesis that the expression of Reg-2 in developing motor neurons is regulated by peripherally-derived factors, the effect of axotomy on Reg-2 expression in the neonatal period was studied. Neonatal rodent motor neurons are developing neurons, which do not assume an adult phenotype until approximately the fifth postnatal day". Unlike their adult counterparts, neonatal motor neurons are particularly S 15 sensitive to peripheral nerve axotomy, with as many as 90% of lumbar motor neurons projecting into the sciatic nerve undergoing apoptosis in the week following sciatic nerve injury on the first postnatal day 15 This sensitivity to axotomy has been attributed to the interruption of retrograde transport of peripherally-derived neurotrophic factors, as survival of neonatal motor neurons following axotomy can be increased to a varying 20 degree by administration of a range of factors, including BDNF' 6 and CNTF" 7 Within 24 hours of peripheral nerve axotomy in newborn rat pups, constitutive Reg-2 protein levels in sciatic motor neurons are markedly reduced compared to the uninjured motor neurons of the opposite side of the spinal cord Fig. 5a). This reduction in Reg-2 expression precedes motor neuron cell death, approximately half of which occurs in the first four days after axotomy 18 The rapid down-regulation of Reg-2 protein following axotomy in the neonate indicates that Reg-2 expression in developing motor neurons is regulated by contact with peripheral targets. Strong candidates for factors produced by peripheral targets to regulate expression of Reg-2 are cytokines of the LIF/CNTF family. Studies on the control of Reg-2 transcription in the pancreas have identified two interleukin-6 response elements (IL-6REs; STAT-binding elements 1 9 in the promoter, region of the rat Reg-2 gene 20 Interleukin-6-related neurotrophic cytokines of the LIF/CNTF family, 13A including LIF, CNTF and cardiotrophin-1 are expressed in the developing and adult peripheral tissues 7 21. 22 All of the members of this sub-family of cytokines signal through receptor complexes containing the common transmembrane units, the IL-6 receptor gpl30 and LIFR, and activate the intracellular Jak-STAT signalling pathway 1 9 23 Targeted disruption of the LIFR gene removes a common component of the LIF, CNTF and CT-1 receptors and thus inhibits signalling by all of those factors during development 7 We analysed E15 mouse embryos homozygous for a disrupted LIFR gene and found that Reg-2 is not expressed by developing motor and sensory neurons in mutant animals (Fig. 5b-e). Reg-2 is expressed in both of those cell types in both wild type littermates and embryos heterozygous for the disrupted gene (Fig. Thus, Reg-2 expression in developing motor and sensory neurons may be dependent on cytokines of the LIF family acting through a receptor complex containing LIFR.
As mentioned above, Schwann cell dedifferentiation and proliferation are essential for neural regeneration in the adult peripheral nervous system 5 6. The classic Schwann cell mitogens, the glial growth factors/neuregulins are consitutively expressed by motor and sensory neurons in early development and adulthood 24 but are not upregulated during regeneration In contrast, we have found that endogenous Reg-2 is only produced during periods of Schwann cell proliferation, that is in the perinatal period and during 20 regeneration. We report here that this Schwann cell mitogen is necessary for regeneration o of Reg-2 containing axons, a large proportion of which are motor axons. Given the regulation of Reg-2 production during development by peripherally-derived factors, including cytokines of the LIF/CNTF family, it is proposed that Reg-2 is an essential component of the neuron-glia interactions underlying development and regeneration of mammalian motor neurons.
Modifications will be apparent to those skilled in the art.
oo* *Doge *oo 14 Throughout this specification the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps.
Any discussion of documents, acts, materials, devices, articles or the like which has been included in the present specification is solely for the purpose of providing a context for the present invention. It is not to be taken as an admission that any or all of these matters form part of the prior art base or were common general knowledge in the field relevant to the present invention as it existed before the priority date of each claim of this application.
ooeo: Sequence homology As indicated above, the present invention concerns the sequence presented as SEQ ID No. 1 or a variant, derivative or homologue thereof in the manufacture of a medicament to act as a Schwann cell mitogen.
Preferably, the homologue can have at least 75% sequence homology identity) with the sequence presented as SEQ ID No. 1.
In particular, the term "homology" as used herein may be equated with the term "identity".
Here, sequence homology can be determined by a simple "eyeball" comparison of SEQ ID No. 1 with another sequence to see if that other sequence has at least 75 identity to SEQ ID No. 1.
Relative sequence homology sequence identity) can also be determined by commercially available computer programs that can calculate homology between two or more sequences. A typical example of such a computer 20 program is CLUSTAL Sequence homology (or identity) may moreover be determined using any suitable homology algorithm, using for example default parameters.
Advantageously, the BLAST algorithm is employed, with parameters set to 25 default values. The BLAST algorithm is described in detail at http://www.ncbi. nih.gov/BLAST/blast help.html, which is incorporated herein by reference. The search parameters are defined as follows, and are advantageously set to the defined default parameters.
Advantageously, "substantial homology" when assessed by BLAST equates to sequences which match with an EXPECT value of at least about 7, preferably at least about 9 and most preferably 10 or more. The default threshold for EXPECT in BLAST searching is usually
SEC
14B BLAST (Basic Local Alignment Search Tool) is the heuristic search algorithm employed by the programs blastp, blastn, blastx, tblastn, and tblastx; these programs ascribe significance to their findings using the statistical methods of Karlin and Altschul (see http://www.ncbi.nih.gov/BLAST/blast_help.html) with a few enhancements. The BLAST programs were tailored for sequence similarity searching, for example to identify homologues to a query sequence.
The programs are not generally useful for motif-style searching. For a discussion of basic issues in similarity searching of sequence databases, see Altschul et at (1994) Nature Genetics 6:119-129.
The five BLAST programs available at http://www.ncbi.nlm.nih.gov perform the following tasks: blastp compares an amino acid query sequence against a protein sequence database; blastn compares a nucleotide query sequence against a nucleotide sequence database; i' 20 blastx compares the six-frame conceptual translation products of a nucleotide query sequence (both strands) against a protein sequence database; tblastn compares a protein query sequence against a nucleotide sequence 25 database dynamically translated in all six reading frames (both strands); tblastx compares the six-frame translations of a nucleotide query sequence against the six-frame translations of a nucleotide sequence database.
S" 30 BLAST uses the following search parameters: 9 9 HISTOGRAM Display a histogram of scores for each search; default is yes.
(See parameter H in the BLAST Manual).
14C DESCRIPTIONS Restricts the number of short descriptions of matching sequences reported to the number specified; default limit is 100 descriptions.
(See parameter V in the manual page). See also EXPECT and CUTOFF.
ALIGNMENTS Restricts database sequences to the number specified for which high-scoring segment pairs (HSPs) are reported; the default limit is If more database sequences than this happen to satisfy the statistical significance threshold for reporting (see EXPECT and CUTOFF below), only the matches ascribed the greatest statistical significance are reported. (See parameter B in the BLAST Manual).
EXPECT The statistical significance threshold for reporting matches against database sequences; the default value is 10, such that 10 matches are expected to be found merely by chance, according to the stochastic model of Karlin and Altschul (1990). If the statistical significance ascribed to a match is greater than the EXPECT threshold, the match will not be reported. Lower EXPECT thresholds are more stringent, leading to fewer chance matches being reported. Fractional values are acceptable. (See parameter E in the BLAST Manual).
S CUTOFF Cutoff score for reporting high-scoring segment pairs. The default o* 9e value is calculated from the EXPECT value (see above). HSPs are reported :".for a database sequence only if the statistical significance ascribed to them is at least as high as would be ascribed to a lone HSP having a score equal to 25 the CUTOFF value. Higher CUTOFF values are more stringent, leading to fewer chance matches being reported. (See parameter S in the BLAST Manual). Typically, significance thresholds can be more intuitively managed using EXPECT.
S' 30 MATRIX Specify an alternate scoring matrix for BLASTP, BLASTX, TBLASTN and TBLASTX. The default matrix is BLOSUM62 (Henikoff Henikoff, 1992). The valid alternative choices include: PAM40, PAM12O, PAM250 and IDENTITY. No alternate scoring matrices are available for BLASTN; specifying the MATRIX directive in BLASTN requests returns an error response.
14D STRAND Restrict a TBLASTN search to just the top or bottom strand of the database sequences; or restrict a BLASTN, BLASTX or TBLASTX search to just reading frames on the top or bottom strand of the query sequence FILTER Mask off segments of the query sequence that have low compositional complexity, as determined by the SEG program of Wootton Federhen (1993) Computers and Chemistry 17:149-163, or segments consisting of short-periodicity internal repeats, as determined by the XNU program of Claverie States (1993) Computers and Chemistry 17:191-201, or, for BLASTN, by the DUST progarn of Tatusov and Lipman (see http://www.ncbi.nlm.nih.gov). Filtering can eliminate statistically significant but biologically uninteresting reports from the blast output hits against common acidic-, basic- or proline-rich regions), leaving the more biologically interesting regions of the query sequence available for specific matching against database sequences.
Low complexity sequence found by a filter program is substituted using the letter in nucleotide sequence "NNNNNNNNNNNNN") and the letter 20 in protein sequences "XXXXXXXXX").
C
Filtering is only applied to the query sequence (or its translation products), Snot to database sequences. Default filtering is DUST for BLASTN, SEG for other programs.
S .It is not unusual for nothing at all to be masked by SEG, XNU, or both, when applied to sequences in SWISS-PROT, so filtering should not be expected to always yield an effect. Furthermore, in some cases, sequences are masked in their entirety, indicating that the statistical significance of any matches 30 reported against the unfiltered query sequence should be suspect.
NCBI-gi Causes NCBI gi identifiers to be shown in the output, in addition to the accession and/or locus name.
SEC
104 A0 .OT 14E Most preferably, sequence comparisons are conducted using the simple BLAST search algorithm provided at http://www.ncbi.nlm.nih.gov/BLAST.
Other computer program methods to determine identify and similarity between the two sequences include but are not limited to the GCG program package (Devereux et al 1984 Nucleic Acids Research 12: 387 and FASTA (Atschul et al 1990 J Molec Biol 403-410).
Medicaments As indicated above, the present invention concerns the sequence presented as SEQ ID No. 1 or a variant, derivative or homologue thereof in the manufacture of a medicament to act as a Schwann cell mitogen.
Here, the pharmaceutical compositions may comprise one or more of a pharmaceutically acceptable diluent, carrier, excipient or adjuvant (including combinations thereof).
The pharmaceutical compositions may be for human or animal usage and 20 will typically comprise any one or more of a pharmaceutically acceptable S* diluent, carrier, excipient or adjuvant. The choice of pharmaceutical carrier, excipient or diluent can be selected with regard to the intended route of administration and standard pharmaceutical practice. The pharmaceutical compositions may comprise as or in addition to the carrier, excipient or 25 diluent any suitable binder(s), lubricant(s), suspending agent(s), coating a.
agent(s), solubilising agent(s).
a.
Where appropriate, the pharmaceutical compositions can be administered by inhalation, in the form of a suppository or pessary, topically in the form of a lotion, solution, cream, ointment or dusting powder, by use of a skin patch, orally in the form of tablets containing excipients such as starch or lactose, or in capsules or ovules either alone or in admixture with excipients, or in the form of elixirs, solutions or suspensions containing flavouring or colouring agents, or they can be injected parenterally, for example intracavernosally, intravenously, intramuscularly or subcutaneously. For parenteral SiRAL 1 104 X, T ON administration, the compositions may be best used in the form of a sterile aqueous solution which may contain other substances, for example enough salts or monosaccharides to make the solution isotonic with blood. For buccal or sublingual administration the compositions may be administered in the form of tablets or lozenges which can be formulated in a conventional manner.
Manufacture The protein of the present invention may be made by synthetic chemical reaction(s) and/or by use of recombinant DNA techniques.
All publications mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described methods and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the 20 invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments.
""0Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related fields are intended to be within the scope of the following claims.
oo ,r
REFERENCES
1. Fawcett, J.W. Keynes, R.J. Peripheral nerve regeneration. Ann. Rev.
Neurosci., 13, 43-60 (1990).
2. Scherer, S.S. Salzer, J.L. Axon-Schwann cell interactions during peripheral nerve degeneration and regeneration, in Glial Cell Development (eds. Jessen, K.R. Richardson, BIOS, Oxford, (1996).
3. Liang, et al. Differential display using one-base anchored oligo-dT primers.
Nuc. Acids Res., 22, 5763-5764 (1994).
oo 4. Iovanna, Orelle, Keim, V. Dagom, Messenger RNA sequence and 15 expression of rat pancreatitis-associated protein a lectin-related protein overexpressed during acute experimental pancreatitis. J. Biol. Chem., 266, 24664-24669 (1991).
5. Hall, S.M. The effect of inhibiting Schwann cell mitosis on the re-innervation of *o acellular autografts in the peripheral nervous system of the mouse. Neuropath. Appl.
20 Neurobiol., 12, 401-414 (1986).
6. Reynolds, M.L. Woolf, C.J. Reciprocal Schwann cell-axon interactions. Curr.
Opin. Neurobiol., 3, 683-693 (1993).
7. Li, Sendtner, M. Smith, A. Essential function of LIF receptor in motor neurons. Nature, 378, 724-727 (1995).
8. Frigerio, Dusetti, Keim, Dagorn, Iovanna, J.L.
Identification of a second rat pancreatitis-associated protein. Messenger RNA cloning, gene structure, and expression during acute pancreatitis. Biochemistry, 32, 9236-9241 (1993).
9. Frigerio, Dusetti, Garrido, Dagorn, Iovanna, The pancreatitis-associated protein-I (PAP-m), a new member of the PAP gene family.
Biochim. Biophys. Acta, 1216, 329-331 (1993).
Watanabe, et al. Pancreatic beta-cell replication and amelioration of surgical diabetes by Reg protein. Proc. Natl. Acad. Sci. USA, 91, 3589-3592 (1994).
11. de la Monte, Ozturk, M. Wands, J.R. Enhanced expression of an exocrine pancreatic protein in Alzheimer's disease and the developing human brain. J.
Clin. Invest., 86, 1004-1013 (1990).
e **o 12. Dumoulin, Raivich, Streut, W.J. Kreutzberg, G.W. Differential regulation of calcitonin gene-related peptide (CGRP) in regenerating rat facial nucleus and 15 dorsal root ganglion. Eur. J. Neurosci., 3, 338-342 (1991).
13. Eccleston, P.A. Regulation of Schwann cell proliferation: mechanisms involved in peripheral nerve development. Exp. Cell Res., 199, 1-9 (1992).
20 14. Weinmaster, G. Lemke, G. Cell-specific cyclic AMP-mediated induction of the PDGF receptor. EMBO J, 9, 915-920 (1990).
o Greensmith, L. Vrbov=E1, G. Motoneurone survival: a functional approach.
Trends Neurosci., 19, 450-455 (1996).
16. Yan, Elliott, J. Snider, W.D. Brain-derived neurotrophic factor rescues spinal motor neurons from axotomy-induced cell death. Nature, 360, 753-759 (1992).
17. Sendtner, Kreutzberg, G.W. Thoenen, H. Ciliary. neurotrophic factor prevents the degeneration of motor neurons after axotomy. Nature, 345, 440-441 (1990).
17 18. Schmalbruch, H. Rosenthal, A. Neurotrophin-4/5 postpones the death of injured spinal motoneurons in newborn rats. Brain=20Res., 700, 254-260 (1995).
19. Schindler, C. Darnell Jr., J.E. Transcriptional responses to polypeptide ligands: the JAK-STAT pathway. Ann. Rev. Biochem., 64, 621-651 (1995).
Dusetti, Ortiz, Mallo, Dagorn, Iovanna, J.L.
Pancreatitis-associated protein (PAP an acute phase protein induced by cytokines. J.
Biol. Chem., 270, 22417-22421 (1995).
21. Banner, L.R. Patterson, P.H. Major changes in the expression of the mRNAs for cholinergic differentiation factor/leukaemia inhibitory factor and its receptor after injury to adult peripheral nerves and ganglia. Proc.Natl. Acad. Sci. USA, 91, 7109-7113 (1994).
o O 22. Pennica, et al. Cardiotrophin-1, a cytokine present in embryonic muscle, supports long-term survival of spinal motoneurons. Neuron, 17, 63-74 (1996).
23. Stahl, et al. Association and activation of Jak-Tyk kinases by 20 CNTF-LIF-OSM-IL-6 b receptor components. Science, 263, 92-95 (1994).
24. Gassmann, M. Lemke, G. Neuregulins and neuregulin receptors in neural development. Curr. Opin. Neurobiol., 7, 87-92 (1997).
25. Carroll, Miller, Frohnert, Kim, S.S. Corbett, J.A.
Expression of neuregulins and their putative receptors, ErbB2 and ErbB3, is induced during Wallerian degeneration. J. Neurosci., 17, 1642-1659 (1997).
26. Jenkins, R. Hunt, S.P. Long term increases in the levels of c-jun mRNA and Jun protein like immunoreactivity in motor and sensory neurons following axon damage.
Neurosci. Lett., 129, 107-111 (1991).
18 27. Altschul, Gish, Miller, Myers, E.W. Lipman, D.J. Basic local alignment search tool. J. Mol. Biol., 215, 403-410 (1990).
28. Wisden, Morris, B.J. Hunt, S.P. In situ hybridization with synthetic DNA probes, in Molecular Neurobiology. A Practical Approach (eds. Chad, J. Wheal, H.) IRL Press, Oxford, (1991).
29. De Felipe, C. Hunt, S.P. The differential control of c-jun expression in regenerating sensory neurons and their associated glial cells. J. Neurosci., 14, 2911-2923 (1994).
30. Chakraborty, et al. Plasma-clearance, tissue uptake and expression of pituitary peptide 23/pancreatitis-associated protein in the rat. J. Endocrinol., 145, 461-469 (1995).
SEQUENCES
SEQ I.D. No. 1 Protein: MLHRLAFPVMSWMLLSCTJMLLSQVQGEDSPKKI
PSARISC
PKGSQAYGSYCYALFQ IPQTWFDAELACQKRPEGHLVSVL NVAEAS FLASMVKNTGNSYQYTW IGLHIDPTLGGE PNGGGW
EWSNNDIMNYVNWERNPSTALDP-GFCGSLSRSSGFLRWRD
TTCEVKLPYVCKFTG
t SEQ ID No.2 Nucleotide Sequence: 1 20 61 121 181 241 301 361 421 481 541 601 661 721 781 aaaaccatcc tatgttgcat cttatcacag ccccaaaggc ctggtttgat caatgtagct atatac ctgg ggagtggagt cttagaccgc taccacatgt agcaaacagc gcgtagaaaa attttgtata aaatcgcccg cgcttggcct gtgcaaggag tcccaggcat gcagaactgg gaagcttcat attggactc aacaatgaca ggattctgtg gaagtgaagt tttagtttgt agtgtattct agttgtgtc caagacagct tcccagtcat aagactctcc atggctccta cctgccagaa t cttggcatc atgaccccac taatgaatta gcagcttgtc tgccctacgt cctgaagcac atctacagtc tcatgtcttg aaggaggagc gtcctggatg gaagaaaata ctgctatgcc gagacctgaa catggtcaag tcttggtgga tgtcaactgg aagatcttct ctgcaaattt atcctgtcaa cata ttggag gaaagcagta agaaagatga ctgctctcct ccctctgcac ctgtttcaga ggacaccttg aacactggaa gaacccaatg gagaggaacc ggatttctaa acaggttaaa ggggcaaaat ctctaatcat ataaacctca tgagagttaa gcctgatgct gcattagttg taccacagac tatctgtgct acagctacca gaggtggatg catctactgc gatggagaga attaCCagaC atgaagactt tctttagcca gtc tct cttc
Claims (8)
1. Use of a protein comprising the sequence presented as SEQ ID No. 1 or a variant, derivative or homologue thereof as hereinbefore described in the manufacture of a medicament to act as a Schwann cell mitogen.
2. A medicament comprising a protein comprising the sequence presented as SEQ ID No. 1 or a variant, derivative or homologue thereof as hereinbefore described optionally admixed with a pharmaceutically acceptable carrier, diluent or excipient.
3. A medicament comprising a protein comprising the sequence presented as SEQ ID No. 1 or a variant, derivative or homologue thereof as hereinbefore described optionally admixed with a pharmaceutically acceptable carrier, diluent or excipient, and wherein the protein is in an effective amount to act as a Schwann cell mitogen.
4. A method of treatment comprising administering to a subject a protein comprising the sequence presented as SEQ ID No. 1 or a variant, derivative or 20 homologue thereof as hereinbefore described and wherein the protein affects the development repair and/or regeneration) of neuronal cell or tissue.
5. A method of treatment comprising administering to a subject a protein comprising the sequence presented as SEQ ID No. 1 or a variant, derivative or S. 25 homologue thereof as hereinbefore described and wherein the protein acts as a Schwann cell mitogen.
6. A method of treatment comprising administering to a subject a protein comprising the sequence presented as SEQ ID No. 1 or a variant, derivative or 30 homologue thereof as hereinbefore described and wherein the protein is in an amount to cause regeneration of at least some neuronal cells or tissue.
9. 7. A process of repairing and/or regenerating a neuronal cell or tissue, the process comprising contacting a damaged neuronal cell or tissue with a protein 35 comprising the sequence as SEQ ID No. 1 or a variant, derivative or 21 homologue thereof as hereinbefore described, and allowing repair and/or regeneration of at least some of the neuronal cell or tissue. 8. Use of a Schwann cell mitogen substantially as described herein. 9. A medicament substantially as described herein. 9. A method of treatment substantially as described herein. A method of treatment substantially as described herein.
11. A process of repairing and/or regenerating a neuronal cell or tissue substantially as described herein. Dated this fifth day of August 2002 University College London Patent Attorneys for the Applicant: F B RICE CO *e o*
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9719796 | 1997-09-17 | ||
GBGB9719796.6A GB9719796D0 (en) | 1997-09-17 | 1997-09-17 | Medicament |
Publications (2)
Publication Number | Publication Date |
---|---|
AU3839797A AU3839797A (en) | 1999-04-01 |
AU754352B2 true AU754352B2 (en) | 2002-11-14 |
Family
ID=10819228
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU38397/97A Expired - Fee Related AU754352B2 (en) | 1997-09-17 | 1997-09-22 | Medicament |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0903147A3 (en) |
AU (1) | AU754352B2 (en) |
CA (1) | CA2215898A1 (en) |
GB (3) | GB9719796D0 (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5436169A (en) * | 1990-04-20 | 1995-07-25 | Institut National De La Sante Et De La Recherche Medicale | Protein associated with acute pancreatitis agents for the screening of acute pancreatitis |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU4837990A (en) * | 1988-12-21 | 1990-07-10 | General Hospital Corporation, The | Method of detecting neurological disease or dysfunction |
US5716930A (en) * | 1991-04-10 | 1998-02-10 | Ludwig Institute For Cancer Research | Glial growth factors |
GB9217316D0 (en) * | 1992-08-14 | 1992-09-30 | Ludwig Inst Cancer Res | Schwann cell mitogenic factor,its preparation and use |
JPH06135998A (en) * | 1992-10-22 | 1994-05-17 | Shionogi & Co Ltd | Pancreatitis-related protein of human and mouse |
-
1997
- 1997-09-17 GB GBGB9719796.6A patent/GB9719796D0/en not_active Ceased
- 1997-09-19 CA CA002215898A patent/CA2215898A1/en not_active Abandoned
- 1997-09-22 AU AU38397/97A patent/AU754352B2/en not_active Expired - Fee Related
-
1998
- 1998-09-16 EP EP98307522A patent/EP0903147A3/en not_active Withdrawn
- 1998-09-16 GB GB9820193A patent/GB2329335B/en not_active Expired - Fee Related
-
2000
- 2000-01-28 GB GBGB0002114.7A patent/GB0002114D0/en not_active Ceased
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5436169A (en) * | 1990-04-20 | 1995-07-25 | Institut National De La Sante Et De La Recherche Medicale | Protein associated with acute pancreatitis agents for the screening of acute pancreatitis |
Non-Patent Citations (2)
Title |
---|
J. IOVANNA ET AL., J. OF BIOL. CHEM, 266(36) PP. 24664-69 * |
T. KAMIMURA ET AL., GENE, 118, 1992, PP 299-30 * |
Also Published As
Publication number | Publication date |
---|---|
EP0903147A3 (en) | 2002-02-27 |
AU3839797A (en) | 1999-04-01 |
GB0002114D0 (en) | 2000-03-22 |
GB9820193D0 (en) | 1998-11-11 |
GB9719796D0 (en) | 1997-11-19 |
CA2215898A1 (en) | 1999-03-17 |
EP0903147A2 (en) | 1999-03-24 |
GB2329335A (en) | 1999-03-24 |
GB2329335B (en) | 2000-06-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Livesey et al. | A Schwann cell mitogen accompanying regeneration of motor neurons | |
Dowsing et al. | Leukemia inhibitory factor is an autocrine survival factor for Schwann cells | |
Pearlman et al. | New directions for neuronal migration | |
Epstein | of Down Syndrome | |
Klein | Role of neurotrophins in mouse neuronal development | |
Ebadi et al. | Neurotrophins and their receptors in nerve injury and repair | |
Heumann et al. | Transgenic activation of Ras in neurons promotes hypertrophy and protects from lesion-induced degeneration | |
Linker et al. | Function of neurotrophic factors beyond the nervous system: inflammation and autoimmune demyelination | |
Ceni et al. | Neurotrophins in the regulation of cellular survival and death | |
Thyagarajan et al. | Genetically altered mouse models: the good, the bad, and the ugly | |
Chaisuksunt et al. | Axonal regeneration from CNS neurons in the cerebellum and brainstem of adult rats: correlation with the patterns of expression and distribution of messenger RNAs for L1, CHL1, c-jun and growth-associated protein-43 | |
DK2276778T3 (en) | Neurotrophic factor MANF as well as applications thereof | |
Tang et al. | A BAC transgenic mouse model reveals neuron subtype-specific effects of a Generalized Epilepsy with Febrile Seizures Plus (GEFS+) mutation | |
Manitt et al. | Peri-pubertal emergence of UNC-5 homologue expression by dopamine neurons in rodents | |
Decressac et al. | Neuropeptide Y modifies the disease course in the R6/2 transgenic model of Huntington's disease | |
Alleva et al. | An updated role for nerve growth factor in neurobehavioural regulation of adult vertebrates | |
KR20090123873A (en) | Use of semaphorin 6a for promoting myelination and oligodendrocyte differentiation | |
Martin et al. | Glial reactivity in ciliary neurotrophic factor-deficient mice after optic nerve lesion | |
Graham et al. | Leukemia inhibitory factor blocks expression of Crx and Nrl transcription factors to inhibit photoreceptor differentiation | |
JPWO2008072781A1 (en) | Method for suppressing or treating memory impairment in mammals | |
Hobson et al. | Galanin acts as a trophic factor to the central and peripheral nervous systems | |
US20080031870A1 (en) | Method of proliferation in neurogenic regions | |
Burger et al. | IL-1Ra | |
AU754352B2 (en) | Medicament | |
JP2007504840A5 (en) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC1 | Assignment before grant (sect. 113) |
Owner name: UNIVERSITY COLLEGE LONDON Free format text: THE FORMER OWNER WAS: MEDICAL RESEARCH COUNCIL |
|
MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |